Supernus Pharmaceuticals, Inc. $SUPN Shares Sold by Aristotle Capital Boston LLC

Aristotle Capital Boston LLC cut its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 62.2% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 305,273 shares of the specialty pharmaceutical company’s stock after selling 503,122 shares during the quarter. Aristotle Capital Boston LLC’s holdings in Supernus Pharmaceuticals were worth $14,589,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Hantz Financial Services Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 81.7% in the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after acquiring an additional 281 shares during the last quarter. USA Financial Formulas purchased a new position in shares of Supernus Pharmaceuticals during the third quarter worth $50,000. EverSource Wealth Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals during the second quarter worth $51,000. Smartleaf Asset Management LLC lifted its position in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in Supernus Pharmaceuticals during the second quarter valued at $55,000.

Supernus Pharmaceuticals Stock Performance

SUPN stock opened at $49.91 on Friday. The firm has a market cap of $2.87 billion, a PE ratio of -73.40, a P/E/G ratio of 1.55 and a beta of 0.70. The firm’s fifty day moving average is $51.22 and its 200 day moving average is $49.07. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $59.68.

Insider Activity

In other news, Director Bethany Sensenig sold 4,475 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $51.01, for a total transaction of $228,269.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $50.41, for a total value of $1,008,200.00. Following the sale, the senior vice president owned 15,496 shares in the company, valued at $781,153.36. This trade represents a 56.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 43,972 shares of company stock worth $2,270,833. 8.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Wall Street Zen downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Sunday, March 8th. Craig Hallum set a $65.00 price objective on Supernus Pharmaceuticals in a report on Wednesday, February 25th. Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a report on Monday, December 29th. Finally, Stifel Nicolaus lifted their price target on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.